CME test answer sheet and evaluation form

Clinical Cornerstone

9 DYSLIPIDEMIA IN METABOLIC SYNDROME

9

Vol. 8, Supplement l

CME Test Answer Sheet and Evaluation Form for DYSLIPIDEMIA IN METABOLIC SYNDROME Volume 8, Supplement 1 Release Date of Activity: March 2006 Expiration Date of Activity for A M A / P R A Credit: March 31, 2008 Estimated Time to Complete this Activity: 2.5 hour(s) Get instant C M E credit(s). Complete your test online and download your certificate now!

Log on to: www.elseviercme.com/getcme/cc/00709 Please Print

Name:

Specialty:

Degree: []MD []DO []PharmD []RPh []NP []RN []BS []PA []Other: Affiliation: Street: City:

State:

Telephone:

Fax:

E-mail:

Signature:

Zip:

(All information is confidential.) C M E Credit Verification

I verify that I have spent _ _

hour(s)/

minutes of actual time working on this CME activity.

No more than 2.5 CME credit(s) will be issued for this activity. P R E - T E S T ASSESSMENT: Please rate your current knowledge of dyslipidemia associated with metabolic syndrome o n a scale of 1 to 5, with 1 being the lowest and 5 the highest.

I 2 3 4 5

CMETEST

(Please circle correct answers.) 1. a b

6. a b c d

11. a b c d

16. a b

2. a b c d

7. a b c d e

12. a b c d

17. a b c d e

3. a b c d

8. a b c d

13. a b

4. a b c d

9. a b c d

14. a b c d

5. a b

10. a b c d e

15. a b

C O U R S E E V A L U A T I O N : Please evaluate the effectiveness of this activity by circling your choice on a scale of I to 5, with I being the lowest and 5 the highest.

1. How well did the material describe the lifestyle and behavioral changes individuals can make to improve dyslipidemia, reduce the risk for progression to type 2 diabetes, and reduce cardiovascular (CV) risk?

I 2 3 4 5

2. Did the material adequately discuss the CV risk factors that need to be targeted with aggressive drug therapy in addition to lifestyle interventions in patients at high risk for CV events?

1 2 3 4 5

$31

Clinical Cornerstone

9

DYSLIPIDEMIA IN METABOLIC SYNDROME

9

Vol. 8, Supplement 1

3. How well did the material explain the characteristics of atherogenic dyslipidemia and the effects of adipose tissue and peroxisome proliferator-activated receptors on insulin action and atherogenesis?

I 2 345

4. How do you rate the overall quality of the activity?

I 2 345

5. How do you rate the educational content of the activity?

I 2 345

6. Was the material presented in this publication fair, objective, balanced, and free of bias in the discussion of any commercial product or service? If no, please comment:

Yes

No

Yes

No

10. Would you be willing to participate in postactivity follow-up surveys?

Yes

No

11. Would you be willing to participate in a phone, e-mail, or in-person discussion exploring ways to improve our CME activities?

Yes

No

7. Suggested topics for future activities:

8. Suggested authors for future activities:

9. After reading this publication, have you decided to change one or more aspects in the treatment of your patients? If yes, what changes will you make? If no, why not?

The EOCME thanks you for your participation in this CME activity. All information provided improves the scope and purpose of our programs and your patients' care.

CME

INSTRUCTIONS

This supplement to Clinical Cornerstone provides 2.5 free AMA PRA Category 1 Credit(s) TM. Log on to www.elseviercme.com/getcme/8-Suppl 1 to print your certificate, or forward the Test Answer Sheet and Evaluation Form to the address shown below. Please allow 6 to 8 weeks for processing. A photocopy of this form is acceptable. (Refer to page(s) 2 - 4 for CME Information.) To get instant CME credit online now, log on to www.elseviercme.com/getcme/cc/00709, or mail the Test Answer Sheet and Evaluation Form to: Elsevier Office of Continuing Medical Education Department 8-Suppl 1 685 Route 202/206 Bridgewater, NJ 08807

Responses for AMA PRA credit must be submitted by March 31, 2008. $32